Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Finerenone approved in Japan for treatment of patients with chronic heart failure – Bayer

Written by | 18 Jan 2026

Bayer announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved finerenone (Kerendia), a non-steroidal, selective mineralocorticoid receptor antagonist (nsMRA), for the treatment of adult patients… read more.

HutchMed highlights publication of Phase III SACHI study results of savolitinib (Orpathys) and osimertinib (Tagrisso) for NSCLC in The Lancet

Written by | 17 Jan 2026

HutchMed highlights that results from the SACHI Phase III trial were published in The Lancet. SACHI is a Phase III study of the savolitinib (Orpathys) and osimertinib (Tagrisso )… read more.

New Libre Assist app feature tackles a top need for people living with diabetes, glucose control: in-the-moment food decisions – Abbott

Written by | 15 Jan 2026

Abbott  unveiled Libre Assist, a groundbreaking feature within the Libre app designed to help the millions of people living with diabetes in the U.S. better understand how the foods… read more.

FDA approval for Wegovy pill (once-daily oral semaglutide 25 mg) to reduce excess body weight and maintain weight reduction long term and to reduce the risk of major adverse CV events – Novo Nordisk

Written by | 13 Jan 2026

Novo Nordisk  announced that the FDA has approved the Wegovy pill (once-daily oral semaglutide 25 mg) to reduce excess body weight and maintain weight reduction long term and… read more.

Daridorexant investigated in women during menopausal transition age with insomnia – Idorsia

Written by | 11 Jan 2026

Idorsia announced the publication of “Efficacy and safety of daridorexant for the treatment of insomnia disorder in women during menopausal transition age: Insights from a randomized controlled trial”… read more.

Pelthos Therapeutics acquires Xeglyze (abametapir) topical treatment for head lice

Written by | 9 Jan 2026

Pelthos Therapeutics Inc. announced it has acquired Xeglyze (abametapir) from Hatchtech Pty Ltd., an Australian biotech company, for $1.8 million. Xeglyze is a pediculicide indicated for the topical… read more.

EU approves Tremfya (guselkumab) for the treatment of children with plaque psoriasis, marking the first paediatric indication for an IL-23 inhibitor – Johnson & Johnson

Written by | 8 Jan 2026

Johnson & Johnson announced that the European Commission (EC) has extended the marketing authorisation for Tremfya (guselkumab) as a subcutaneous treatment to treat moderate to severe plaque psoriasis… read more.

Dupixent (dupilumab) approved in Japan for children aged 6 to 11 years with bronchial asthma – Sanofi

Written by | 7 Jan 2026

The Ministry of Health, Labour and Welfare in Japan has granted marketing and manufacturing authorization for Dupixent (dupilumab) for the treatment of bronchial asthma in children aged 6… read more.

Mounjaro (tirzepatide) receives positive CHMP opinion for on variation to marketing authorisation for treatment of type 2 diabetes – Eli Lilly

Written by | 6 Jan 2026

The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for Mounjaro (tirzepatide). The marketing… read more.

Dovprela (pretomanid) receives positive CHMP opinion for on variation to marketing authorisation for treatment of TB – Viatris

Written by | 5 Jan 2026

The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending a change to the terms of the marketing authorisation for Dovprela. (pretomanid). The marketing… read more.

Caris Life Sciences announces collaboration with Genentech to discover novel therapeutic targets in cancers with high unmet clinical need

Written by | 4 Jan 2026

Caris Life Sciences announced that its therapeutic research arm, Caris Discovery, has entered into a multi-year collaboration and license agreement with Genentech, a member of the Roche Group. In… read more.

Altamira Therapeutics announces market approval of Bentrio nasal spray in China

Written by | 2 Jan 2026

Altamira Therapeutics Ltd. announced that its associate company Altamira Medica has obtained marketing approval from the National Medical Products Administration (NMPA) of China for its Bentrio nasal spray… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.